CML Treatment Breakthroughs: Discover Hope Beyond Daily Medication

Chronic myeloid leukemia (CML) originates in the bone marrow due to a genetic alteration that produces an overactive protein, BCR-ABL1. Historically lethal, targeted therapies have transformed CML into a manageable chronic condition. Today, treatment primarily involves tyrosine kinase inhibitors (TKIs), with new therapies like asciminib emerging in 2025. These advancements enhance patient outcomes, enabling many to achieve treatment-free remission, where therapy can pause after a deep molecular response. Ongoing studies aim to broaden access to clinical trials and innovative treatments, ultimately inspiring hope for enhanced patient care.